Metabolic Obesity in Normal Weight (MONW): Diagnostic Markers Stud

Sponsor
Pomeranian Medical University Szczecin
Study ID
NCT07358533
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Metabolic Syndrome
  • Metabolically Obese Normal Weight
  • Normal Weight Obesity

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 35 Years
Healthy Volunteers
Accepted

Study Details

Metabolically Obese Normal Weight (MONW) represents a phenotype affecting individuals with a normal Body Mass Index (BMI) but characterized by excessive adipose tissue accumulation. This condition is associated with increased cardiovascular risk, insulin resistance, and endothelial dysfunction, yet remains underdiagnosed. This observational longitudinal study aims to comprehensively evaluate the relationship between excessive adipose tissue deposition, endothelial dysfunction, and asprosin concentrations in young women. The study will recruit 176 healthy women aged 18-35 years with normal BMI (\<25 kg/m²). Participants will be divided into two groups based on body fat percentage (PBF) assessed by dual-energy X-ray absorptiometry (DXA): the MONW group (PBF ≥ 35.78%) and the Control group (PBF \< 35.78%). The specific objectives of the study include: * Assessment of vascular endothelial function using flow-mediated dilation (FMD) of the brachial artery. * Evaluation of asprosin as a novel biomarker in the MONW phenotype. * Analysis of biochemical indices including asymmetric dimethylarginine (ADMA) and von Willebrand factor (vWF). * Advanced metabolomic profiling to identify metabolic signatures. Participants will undergo anthropometric measurements, body composition analysis (DXA), and blood sampling for biochemical and hormonal analyses. The study aims to develop predictive models for early cardiovascular risk detection in normal-weight individuals.

Key Dates

First listed
Jan 22, 2026
Start date
Sep 30, 2026
Status verified
Jan 2026
Primary completion
May 31, 2027
Completion
Sep 30, 2029

Study Design

Enrollment
176 participants (estimated)

Arms

  • Arm: MONW Group
    Women with normal BMI (\<25 kg/m²) and excessive body fat percentage (PBF ≥ 35.78%).
  • Arm: Control Group
    Women with normal BMI (\<25 kg/m²) and normal body fat percentage (PBF \< 35.78%).

Primary Outcome Measure

Brachial Artery Flow-Mediated Dilation (FMD) [ Time Frame: Baseline, 12 months ]

Central Contacts

Related Studies